No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
China Securities Co.,Ltd.: Policy encouragement + new technology promotion + overseas opportunities create new chances, maintaining a bullish outlook on the Innovative Drugs industry.
National policies encourage the development of Innovative Drugs, new technologies promote the rapid growth of the Industry, new opportunities arise for going overseas, and there is a continuous Bullish outlook for the Innovative Drugs Industry.
Sinolink: The policy inflection point is clear, suggesting to start increasing allocation in the pharmaceutical sector.
In the segmented Industry, it is recommended to focus on allocating resources to Innovative Drugs and left-side Sectors (such as Medical Device, Traditional Chinese Medicine, Consumer Medical, chain pharmacies, etc.) for opportunities in reverse situations of individual stocks as the two main lines.
The construction of specialized traditional Chinese medicine departments is accelerating, and TCM clinical services maintain high prosperity.
Golden Owl Financial News | According to recent reports from CCTV News on the National Administration of Traditional Chinese Medicine, through a series of measures such as accelerating the construction of Traditional Chinese Medicine advantageous specialties, the high-quality development of county-level Traditional Chinese Medicine Hospitals, and the construction of collaborative hospitals for Chinese and Western medicine, China has now established 1,158 national advantageous specialties in Traditional Chinese Medicine. The next step will be to build a network of advantageous specialties in Traditional Chinese Medicine and create clusters of advantageous specialties, focusing on strengthening the construction of pediatrics, geriatrics, and mental illness specialties, as well as promoting the foundation and quality of county-level Traditional Chinese Medicine hospitals and enhancing grassroots Traditional Chinese Medicine service capabilities. Under the dual drive of policy and clinical demand, the Traditional
GTJA: The centralized procurement of Chinese Patent Medicine is still in the early stages, and quality improvement and expansion are expected to continue to progress.
GTJA released a Research Report stating that the bidding for the third batch of national Chinese Patent Medicine centralized procurement has opened, with the reduction slightly exceeding expectations.
The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.
① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.
The Five-year Shareholder Returns and Company Earnings Persist Lower as Tong Ren Tang Technologies (HKG:1666) Stock Falls a Further 6.9% in Past Week
